WJB001 + paclitaxel + paclitaxel-albumin

WJB001 + paclitaxel + paclitaxel-albumin is an investigational combination therapy under clinical evaluation for advanced solid tumors. WJB001 is a small-molecule inhibitor of Wee1 kinase, a regulator of the G2/M cell cycle checkpoint. Paclitaxel is a microtubule-stabilizing chemotherapeutic agent, and paclitaxel-albumin (nab-paclitaxel/Abraxane) is a nanoparticle albumin-bound formulation of paclitaxel, designed for improved solubility and drug delivery. This combination is being studied for its safety and efficacy, leveraging the potential synergistic effects of Wee1 inhibition and antimitotic chemotherapy to enhance tumor cell death. The primary indications are advanced solid tumors, particularly where conventional chemotherapy is indicated[1][2][8].

Brand names

Abraxane

Other names

nab-paclitaxel